Image by ART-ur/Shutterstock

Researchers at University of Tsukuba have discovered that an immunosuppressive drug affects microglia, the resident immune cells of the brain. In mouse models, the drug reduced levels of guanosine nucleotides, which are essential for cell signaling and morphology. This reduction weakened the activity of small G proteins, leading to changes in microglial shape and function.

Tsukuba, Japan—Microglia are resident immune cells in the central nervous system that participate in the regulation of brain homeostasis throughout life. In early postnatal stages, microglia regulate neural circuit formation, debris clearance, and cerebral vasculature development. Microglia undergo morphological changes during brain development, giving rise to functionally diverse subpopulations. However, the molecular mechanisms underlying these morphological changes have not been fully elucidated.

Our research team previously found that purine metabolism regulates microglial morphology (Okajima et al., eNeuro, 2020). Purine metabolism encompasses the pathways that process purine bases, including adenine and guanine, and it is essential for energy production and nucleic acid synthesis. In this study, we focused on inosine monophosphate (IMP), a key metabolic intermediate that serves as a precursor for adenosine triphosphate and guanosine triphosphate (GTP). Administration of mycophenolate mofetil (MMF), which inhibits IMP conversion, resulted in reduced levels of guanosine nucleotides in the brain, accompanied by decreased activation of small G proteins that regulate the cytoskeleton. Consistently, microglia exhibited fewer cellular processes and reduced morphological complexity.

Microglia continuously extend and retract their processes to sense and communicate with their surrounding environment. Therefore, elucidating the mechanisms governing morphological alterations in microglia may provide critical insights into neurodevelopmental disorders associated with impaired microglial function. These findings further suggest that MMF, a well-established immunosuppressant, could be repurposed to modulate microglial activity, potentially facilitating the development of novel therapeutic strategies targeting microglia.

###
This work was supported by Gout and uric acid foundation (FT), Sumitomo foundation (FT), OnoPharmaceutical foundation for Oncology, Immunology, and Neurology (FT), AMED-PRIME [ADI07313 (FT)], JST SPRING [JPMJSP2124 (RT)] and partly supported by Center for Quantum and Information Life Sciences, University of Tsukuba (FT).

Original Paper

Title of original paper:

Mycophenolate mofetil reduces the branching of microglial processes

Journal:

Molecular Brain

DOI:

10.1186/s13041-025-01271-1

Correspondence

TERUYA Rin-ichiro
Doctoral Program in Biology, Degree Programs in Life and Earth Sciences, Graduate School of Science and Technology, University of Tsukuba

Assistant Professor TSURUTA Fuminori
Institute of Life and Environmental Sciences, University of Tsukuba

Related Link

Institute of Life and Environmental Sciences